BridgeBio’s Achondroplasia Pill Shows ‘Compelling’ Growth and Body Proportionality Benefit

BridgeBio's Infigratinib Shows Significant Growth and Proportionality Benefits in Achondroplasia

BridgeBio Pharma's oral drug, infigratinib, demonstrated significant improvements in both growth velocity and body proportionality in children with achondroplasia during the Phase 3 PROPEL 3 study. The company plans to file a regulatory package in Q3, aiming for an early to mid-2027 launch. Analysts project peak sales of $1 billion, highlighting the drug's "highly differentiated" oral administration and proportionality benefits compared to existing subcutaneous therapies like BioMarin's Voxzogo and Ascendis' Yuviwel. The data, presented at the 2026 International Congress of Children’s Bone Health and published in the New England Journal of Medicine, confirmed a 2.1-cm/year advantage in annualized growth velocity.

• Statistically Significant Body Proportionality Improvement: Infigratinib achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, a finding deemed "compelling" by Jefferies. This outcome is expected to drive meaningful improvements in daily activities and mobility for patients and is optimistically anticipated to be included in the drug's label, setting it apart from competitors.
• Confirmation of Primary Efficacy Endpoint: The PROPEL 3 study's presentation included a readout for its primary efficacy endpoint, confirming topline data released in February. Patients receiving infigratinib showed a 2.1-cm/year advantage in annualized growth velocity compared to placebo, reinforcing the drug's effectiveness in promoting growth in children with achondroplasia.
• Differentiated Oral Option with Market Potential: BridgeBio's infigratinib offers a "highly differentiated" oral treatment option, contrasting with the currently approved daily/weekly subcutaneous injections. Jefferies conservatively estimates peak sales of $1 billion for infigratinib in achondroplasia, underscoring its potential to capture a significant market share due to its unique benefits and administration route.

Infigratinib's PROPEL 3: Unveiling Growth and Proportionality Benefits

Recent clinical investigation in achondroplasia has accelerated substantially, with multiple interventional studies and real-world registries now generating robust efficacy and safety data across diverse patient populations. The therapeutic landscape spans approved agents, emerging molecular therapies, and novel indications, collectively advancing the evidence base beyond symptomatic management toward disease-modifying precision medicine.

• CrescNet Registry Achondroplasia Module (2026) — Vosoritide: This multinational real-world registry, established in 2021 across 32 tertiary centers, enrolled 486 participants as of May 2025, with analysis conducted on 186 vosoritide-treated and 73 untreated individuals with genetically confirmed achondroplasia. Mean height standard deviation score — referenced to an untreated European achondroplasia population — increased significantly from baseline at 1, 2, and 3 years post-initiation (P≤0.0001), with growth data consistent with clinical trial findings.

• Six Clinical Trials Safety and Efficacy Analysis (2026) — Vosoritide: Pooling data from 156 patients with achondroplasia aged 3 months to 18 years treated with vosoritide (2.5–30 µg/kg/day in Phase II; 15 µg/kg in all other studies), this analysis confirmed significant improvements in annualized growth velocity (AGV), height Z-score, and standing height versus placebo. Adverse events were recorded in all 156 patients but were universally mild (Grade 1), self-limiting, and confined to local injection site reactions.

• Six Clinical Trials Complications Analysis (2026) — Vosoritide: Among 230 participants receiving vosoritide through August 2024 (68 aged <5 years, exposure 289.1 person-years; 162 aged ≥5 years, exposure 834.5 person-years), the prevalence of most achondroplasia-related complications was consistent with or lower than natural history rates. Incidence of leg malalignment, foramen magnum stenosis, spinal stenosis, kyphosis, lordosis, hydrocephalus, ENT complications, and pain were generally reduced. Foramen magnum decompression frequency was 3.0% overall (5.9% in those initiating treatment before age 2 years), and crude mortality was lower than natural history rates.

• Meta-Analysis of Vosoritide Studies (2026) — Vosoritide: Encompassing 13 studies (RCTs, cohort studies, case reports, and case series) at the approved dose of 15 µg/kg/day, this meta-analysis reported an AGV of 5.72 cm/year (95% CI: 5.51–5.94) at 12 months and a mean height Z-score improvement of 0.28 (95% CI: 0.16–0.4), with no significant difference between sexes. The most common adverse events were injection site reactions (51%) and gastrointestinal symptoms (50%), with the overall adverse event profile characterised as mild to moderate.

• Real-World Single-Center Cohort Study (2026) — Vosoritide: In 25 children with achondroplasia (17 boys; age range 2.9–14.3 years) treated for a mean of 12.7 months, mean height Z-scores improved significantly from −0.62 ± 1.09 to −0.24 ± 1.20 (P < .001), and mean arm span Z-score increased from −1.28 ± 0.93 to −0.96 ± 0.91 (P = .007). Mean Δ height and Δ arm span Z-score gains were +0.38 ± 0.45 and +0.32 ± 0.48, respectively. A subgroup analysis of 8 patients with prior limb-lengthening surgery versus 17 without demonstrated no significant differences in outcomes. No serious treatment-related adverse events were reported.

• Phase II Basket Trial (2026) — Vosoritide: This prospective academic trial enrolled 30 pre-pubertal children aged 3–11 years with RASopathy, ACAN, or NPR2 deficiency and height <−2.25 SD, following a 6-month observation period with 12 months of subcutaneous vosoritide 15 µg/kg/day. AGV increased from 4.53 ± 1.61 cm/year to 8.09 ± 1.58 cm/year (P < 0.0001), corresponding to a 4.0 SD increase in age- and sex-adjusted AGV Z-score (95% CI: 3.08–4.91; P < 0.0001), with gains observed across all genetic subgroups. Height increased by 0.65 SD (95% CI: 0.53–0.77) in the treatment versus observation period (P < 0.0001). Short-term safety was reassuring, with mild injection site reactions as the predominant adverse event; however, with longer use, five subjects discontinued due to adverse events including three cases of slipped capital femoral epiphysis and four cases of genu valgum.

• Sleep-Disordered Breathing Study (2025) — Precision Therapies (Vosoritide, Infigratinib, Recifercept): This retrospective study at The Royal Children's Hospital, Australia (2013–2024) assessed 80 children with achondroplasia (54% female; 95% with confirmed molecular diagnosis), accumulating an average of 3.6 polysomnographies per child. Among 27 children who received precision therapy (vosoritide n=18, infigratinib n=8, recifercept n=1), median respiratory disturbance index per hour improved from 2.7 (IQR: 0.9–4.8) to 1.1 (IQR: 0.3–2.6) after 1 year of treatment.

• Comparative Treatment Review (2025) — Vosoritide, Infigratinib, Navepegritide: A comparative analysis of three investigational agents in children aged 5 years and older reported improved AGV versus baseline of 1.7 cm/year with vosoritide (injectable CNP analog; reduces MAPK pathway overactivation), 6.0 cm/year with infigratinib (oral FGFR1-3 inhibitor; directly suppresses downstream signaling), and 5.4 cm/year with navepegritide (long-acting CNP prodrug; sustains MAPK inhibition). All three therapies demonstrated favorable safety profiles; reported adverse events included nasopharyngitis for infigratinib, injection site reactions for navepegritide, and radius fracture, adenoidal hypertrophy, and sleep apnea for vosoritide. Direct cross-trial comparisons remain limited, and head-to-head studies are needed to evaluate relative efficacy and combination strategies.

Designing PROPEL 3: A Closer Look at Trial Methodology

The achondroplasia clinical trial landscape encompasses a range of interventional designs—from pivotal phase 3 randomized controlled trials to early-phase dose-escalation and proof-of-concept studies—spanning pediatric populations from infancy through adolescence. Key trials have evaluated vosoritide, navepegritide (TransCon CNP), and combination regimens, with primary endpoints centered on annualized growth velocity (AGV) and height Z-score change. Real-world registries and meta-analyses have further supplemented the controlled trial evidence base.

Infigratinib's Differentiated Role in Achondroplasia Treatment Landscape

Published comparative data situate investigational therapies — particularly vosoritide and infigratinib — as mechanistically targeted alternatives to the historical standard of care, which has relied primarily on growth hormone (GH) therapy and surgical limb lengthening. A 2023 systematic review confirmed that vosoritide, GH, and limb lengthening all confer measurable benefits for height or growth velocity; however, the evidence base and benefit-risk profiles differ substantially across modalities. Vosoritide, a recombinant C-type natriuretic peptide analogue approved by both the FDA and EMA, demonstrated significant improvements in annualized growth velocity, height Z-score, and standing height versus placebo in patients aged 3 months to 18 years at a dose of 15 µg/kg/day. CrescNet registry data from 2026 (n=156) showed statistically significant increases in mean height standard deviation score at 1, 2, and 3 years post-initiation (P≤0.0001), with adverse events universally mild (grade 1), self-limiting, and largely confined to local injection site reactions. In contrast, long-term efficacy data for GH remain inconclusive, and its use does not address cranial skeletal abnormalities such as midface hypoplasia or foramen magnum stenosis — a clinically meaningful limitation given the neurological sequelae associated with these features.

Surgical limb lengthening remains the most established intervention for stature gain but carries a substantially higher procedural burden. A 2026 meta-analysis of 14 studies encompassing 1,149 patients reported mean femoral, tibial, and humeral gains of 8.85 cm, 7.36 cm, and 8.38 cm, respectively, with a mean external fixator duration of 7.71 months and an overall complication rate of 56.1%. A 2021 study of simultaneous bilateral femoral and tibial lengthening (65 procedures across 50 patients) found that distributing the lengthening across both segments reduced total external fixator time, though 76% of patients experienced at least one adverse event, with 45% of those requiring additional surgical intervention. Despite these risks, pooled Paediatric Quality of Life Inventory scores reached 75.69, reflecting moderate improvement in functional outcomes. Meclozine, an oral anti-motion-sickness agent identified through drug repositioning, has also shown preclinical promise — suppressing FGFR3 signaling and rescuing short-limbed phenotype in transgenic mouse models at 2 mg/kg/day — though human tolerability and long-term safety data remain unestablished.

Infigratinib, a direct FGFR3 receptor tyrosine kinase inhibitor, offers a mechanistically distinct approach with implications extending beyond long bone growth. A 2024 mouse model study demonstrated that early postnatal administration (from day 1, approximating immediate postnatal intervention in humans) significantly restored both cranial development and foramen magnum stenosis phenotype — deficits for which no approved pharmacological therapy currently exists. Late postnatal treatment (from day 4, equivalent to approximately 5 months in humans) yielded only weak to no cranial rescue, despite comparable improvements in long bone growth across both protocols. This timing dependency reflects the premature fusion of skull base synchondroses occurring immediately after birth and provides a compelling rationale for investigating prenatal therapeutic strategies. Taken together, the published evidence highlights a landscape in which investigational agents targeting FGFR3 signaling — particularly when administered early — may address skeletal manifestations that current standard-of-care approaches leave unresolved, though data gaps persist regarding long-term outcomes, cost-effectiveness, and effects through puberty.